FDA
-
-
-
-
-
-
-
Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2026
-
-
-
-
-
-
-
Appili Therapeutics Announces Results of Annual and Special Meeting of Shareholders
-
-
-
-
-
-
-
Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2025
-
-
-
-
-
-
-
Aditxt’s Acquisition Target Appili Therapeutics Will Hold a Special Meeting of Shareholders on November 6, 2024, to Vote on the Transaction and Secure Appili’s Shareholder Approval
-
-
-
-
-
-
-
Aditxt, Inc (ADTX) to Acquire Appili Therapeutics
-
-
-
-
-
-
-
Appili Therapeutics Announces U.S. FDA Approval of LIKMEZ™ (ATI-1501) Metronidazole Oral Suspension
-
-
-
-
-
-
-
Appili Therapeutics Appoints Dr. Gary Nabors as Chief Development Officer
-
322,212 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

